New drug duo takes on advanced lung cancer
NCT ID NCT07590531
First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This study tests a new combination of two drugs, AMT116 and ivosimab, in people with advanced non-small cell lung cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the combination shrinks tumors. About 118 adults aged 18 to 75 will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
Contact
-
Zhejiang cancer hospital
RECRUITINGHangzhou, Zhejiang, China
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart cancer therapy: tailoring lung cancer treatment with a simple blood test
- New drug cocktail targets tough lung cancer
- Blood test could speed up lung cancer treatment decisions
- Could a common antioxidant boost chemo for advanced lung cancer?
- Lung cancer surgery risks under the microscope: 1,000 patients studied
- New study aims to crack the code on cancer drug resistance